Scil Technology – a New German
Biopharmaceutical Company – is Launched by the Scil
Group
Irina Staatz-Granzer is Named Managing
Director
MARTINSRIED, Germany, October 28, 2003 – Scil
Technology, a new company focused on the development of tissue
regeneration products, was officially launched today. The Company
was created from the Scil Group and has one shareholder, BioNet
Holding GmbH. At the same time, Scil Technology announced that
it has appointed Dr Irina Staatz-Granzer as Managing Director
of the new Company.
Scil Technology will develop innovative products for bone
and cartilage regeneration in dentistry and orthopaedics, combining
synthetic, resorbable scaffolds with bone and cartilage specific
proprietary growth factors. The Company has a proprietary protein
coating technology that ensures a homogenous and stable coating
of growth factor on various matrices and implants, allowing
for controlled release of the growth factors in vivo.
Dr Irina Staatz-Granzer, Managing Director of Scil Technology,
commented:
“I am delighted to be taking on this challenging role within Scil Technology,
a new company at the forefront of pioneering regenerative dental and orthopaedic
biomaterials. With its experienced development team, Scil Technology starts its
life well placed to become one of the leading regenerative companies in the world.”
Dr Staatz-Granzer has more than 15 years' industrial experience
in the pharmaceutical industry. She joined the Scil Group in
2002 as Vice President of Business Development of Scil Biomedicals.
Before joining Scil she served as Director of Business Development
at Knoll later Abbott. Prior to that, she held leading management
positions in analytical development, international marketing
and business development at Hermal Kurt Herrmann, a former
100% subsidiary of Merck KGaA, later Boots Healthcare International.
Scil Technology is a subsidiary of Bionet Holding GmbH and
is the major shareholder of Scil Proteins GmbH. Scil Technology
is located in Martinsried/Munich.
About Scil Technology GmbH
Scil Technology is a private biopharmaceutical development
company focused on dental and orthopaedic tissue regeneration
with a particular emphasis on bone and cartilage repair. The
Company’s lead therapeutic candidates are based on recombinant,
highly specific human growth factors. These are combined with
biodegradable biomaterials to generate local application forms.
Scil Technology’s pipeline for dentistry includes products
that are targeted at periodontal disease, dental implantology
and maxillofacial surgery. Orthopaedic products are developed
for spinal fusion, traumatic lesions of bone and cartilage
tissue and osteoarthritis. Scil Technology has emerged
from the Scil Group and is located in the biotechnology cluster
in Martinsried, Germany.
For more information please visit: http://www.scil.com
Contacts
Media relations:
Sue Charles, MA, MBA, CEO
Northbank Communications
t : +44 (0) 20 7886 8152
e: s.charles@northbankcommunications.com
Douglas Pretsell, Ph.D., Senior Account Manager
Northbank Communications
t : +44 (0) 20 7886 8158
e: d.pretsell@northbankcommunications.com
At Scil Technology:
Dr Irina Staatz-Granzer, Managing Director
Scil Technology GmbH
t: +49 (0)89 85651824
e: irina.staatz@scil.com
|
